Biogen (NASDAQ:BIIB) Releases FY 2025 Earnings Guidance

Biogen (NASDAQ:BIIB) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 15.250-16.250 for the period, compared to the consensus EPS estimate of 16.240. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Wells Fargo & Company cut their target price on shares of Biogen from $165.00 to $140.00 and set an “equal weight” rating on the stock in a research note on Thursday. William Blair restated an “outperform” rating on shares of Biogen in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Biogen in a research report on Thursday. TD Cowen reduced their price target on Biogen from $300.00 to $275.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Finally, JPMorgan Chase & Co. lowered their price target on Biogen from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Monday, November 4th. Seventeen analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $216.50.

Biogen Price Performance

Shares of BIIB traded up $0.78 during mid-day trading on Thursday, reaching $134.21. The company had a trading volume of 419,492 shares, compared to its average volume of 1,340,859. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. The company has a market capitalization of $19.56 billion, a P/E ratio of 12.12, a P/E/G ratio of 1.65 and a beta of -0.08. Biogen has a twelve month low of $128.51 and a twelve month high of $238.00. The company’s 50-day moving average is $147.73 and its 200-day moving average is $174.05.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.81%. On average, equities analysts anticipate that Biogen will post 16.42 EPS for the current year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.